Novozymes downgrades following failing sales

After five months into this year, Novozymes disappoints stakeholders and downgrades its 2019 guidance.
Photo: Novozymes/PR
Photo: Novozymes/PR
BY ANDERS LEONHARD

Novozymes' US sales have not panned out, limiting the Danish enzyme producer's growth.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading